Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Aflibercept Products (Eylea; EyleaHD, Ahzantive [aflibercept-mrbb], Enzeevu [Aflibercept-abzv], Eydenzelt [Aflibercept-boav], Opuviz [Aflibercept-yszy], Pavblu [Aflibercept-ayyh], and Yesafili [Aflibercept-jbvf]) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Shoulder Resurfacing | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Afamitresgene Autoleucel (Tecelra) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Sexual Dysfunctions, Assessment and Treatment | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Aducanumab-avwa (Aduhelm) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Sensory Integration Therapy and Auditory Integration Therapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nadofaragene firadenovec-vncg (Adstiladrin) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Secukinumab | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Adoptive Immunotherapy | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Seat Lift Mechanisms and Patient Lifts | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ado-Trastuzumab Emtansine (Kadcyla) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Scleral Shell | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer, Including Comprehensive 3D Mapping with Biopsy | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | SARS-CoV-2 (COVID-19) Antibody Testing | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Sacroiliac Joint Injections | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Brentuximab Vedotin (Adcetris) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Sacral Nerve Neuromodulation/Stimulation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | ADAMTS13, recombinant-krhn (Adzynma) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Rozanolixixumab-noli | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Crizanlizumab-tmca(Adakveo) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Romosozumab-aqqg | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Acupuncture | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Romiplostim | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Rituximab and Biosimilars for Non-Oncologic Indications | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Actigraphy | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Risankizumab-rzaa | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Corticotropin-ACTH: [HP Acthar Gel (repository corticotropin injection), Cortrophin Gel | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Rhinomanometry, Acoustic Rhinometry, Optical Rhinometry and Acoustic Pharyngometry | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tocilizumab (Actemra); Tocilizumab-anoh (Avtozma); Tocilizumab-bavi (Tofidence); Tocilizumab-aazg (Tyenne) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Responsive Neurostimulation for the Treatment of Refractory Focal Epilepsy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Rhinomanometry and Acoustic Rhinometry | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Reslizumab | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Reproductive Techniques and Immunotherapy for Recurrent Fetal Loss | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Balloon and Self-Expanding Absorptive Ostial Dilation for Treatment of Rhinosinusitis | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Renal Denervation for Uncontrolled Hypertension | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Absorbable Nasal Implant for the Treatment of Nasal Valve Collapse | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Remote Electrical Neuromodulation for Migraines | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Paclitaxel (Albumin-Bound) (Abraxane; Paclitaxel Albumin-Bound) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Remdesivir | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | AbobotulinumtoxinA (Dysport) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Reduction Mammaplasty for Breast-Related Symptoms | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Reconstructive Breast Surgery/Management of Breast Implants | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ablation Procedure for Peripheral Neuromas | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Reconstructive Breast Surgery | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Radiofrequency Ablation for Nasal Obstruction and Rhinitis | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Idecabtagene Vicleucel (Abecma) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Ravulizumab-cwvz | Criteria changed |